HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MPLT

MapLight Therapeutics Inc

Last Close
Feb 06  •  04:00PM ET
16.98
Dollar change
+1.28
Percentage change
8.15 %
Healthcare • Biotechnology • USA • NASD
Held by: VTI IWM VXF VTWO SCHA IWO IWN IWC SCHB VTWG
Scroll to Statements
IndexRUT P/E- EPS (ttm)- Insider Own58.62% Shs Outstand45.37M Perf Week-4.01%
Market Cap770.43M Forward P/E- EPS next Y- Insider Trans31.38% Shs Float18.77M Perf Month5.73%
Enterprise Value1.06B PEG- EPS next Q-0.99 Inst Own2.02% Short Float5.78% Perf Quarter6.12%
Income- P/S- EPS this Y- Inst Trans24.31% Short Ratio3.92 Perf Half Y-
Sales- P/B- EPS next Y- ROA- Short Interest1.09M Perf YTD-3.33%
Book/sh-6.04 P/C3.39 EPS next 5Y- ROE- 52W High21.55 -21.21% Perf Year-
Cash/sh5.01 P/FCF- EPS past 3/5Y-60.77% - ROIC- 52W Low12.24 38.73% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.23% 9.48% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM- Oper. Margin- ATR (14)1.51 Perf 10Y-
Dividend Ex-Date- Quick Ratio13.22 Sales Y/Y TTM- Profit Margin- RSI (14)46.40 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio13.22 EPS Q/Q-41.88% SMA20-4.68% Beta- Target Price31.00
Payout- Debt/Eq0.03 Sales Q/Q- SMA50-4.25% Rel Volume0.67 Prev Close15.70
Employees- LT Debt/Eq0.02 EarningsDec 04 BMO SMA200-0.47% Avg Volume276.88K Price16.98
IPOOct 27, 2025 Option/ShortNo / Yes EPS/Sales Surpr.-2055.36% - Trades Volume184,484 Change8.15%
Date Action Analyst Rating Change Price Target Change
Nov-21-25Initiated Stifel Buy $28
Nov-21-25Initiated Morgan Stanley Overweight $34
Nov-21-25Initiated Leerink Partners Outperform $30
Nov-21-25Initiated Jefferies Buy $32
Jan-09-26 07:00AM
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
(GlobeNewswire)
Jan-05-26 07:00AM
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis
(GlobeNewswire)
Dec-16-25 07:00AM
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
(GlobeNewswire)
Dec-04-25 07:00AM
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
(GlobeNewswire) +8.39%
Nov-07-25 07:26PM
MapLight Therapeutics, Gold Royalty, and More Stocks See Action From Activist Investors
(Barrons.com)
09:06AM Loading…
Oct-29-25 09:06AM
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
(GlobeNewswire)
Oct-26-25 05:30PM
MapLight Therapeutics Announces Pricing of Initial Public Offering
(GlobeNewswire)
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Malenka Robert C.DirectorFeb 02 '26Sale18.027,039126,843358,234Feb 04 09:15 PM
Malenka Robert C.DirectorFeb 03 '26Sale18.00118358,233Feb 04 09:15 PM
ROBERT MALENKADirectorFeb 03 '26Proposed Sale18.00118Feb 03 04:15 PM
ROBERT MALENKADirectorFeb 02 '26Proposed Sale18.027,039126,835Feb 02 04:37 PM
Malenka Robert C.DirectorJan 29 '26Sale18.5521,262394,410371,885Jan 30 08:50 PM
Malenka Robert C.DirectorJan 28 '26Sale18.656,524121,704393,147Jan 30 08:50 PM
Malenka Robert C.DirectorJan 30 '26Sale18.116,612119,743365,273Jan 30 08:50 PM
ROBERT MALENKADirectorJan 30 '26Proposed Sale18.116,612119,737Jan 30 04:17 PM
ROBERT MALENKADirectorJan 29 '26Proposed Sale18.5521,262394,470Jan 29 04:06 PM
ROBERT MALENKADirectorJan 28 '26Proposed Sale18.656,524121,690Jan 28 04:20 PM
Novo Holdings A/S10% OwnerOct 28 '25Buy17.00952,94116,199,9973,686,622Oct 30 04:31 PM
Catalyst4, Inc.10% OwnerOct 28 '25Buy17.005,441,17692,499,99219,697,464Oct 29 04:16 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.